Data were obtained from third parties for this analysis. Several of the participating studies required specific data sharing agreements from their host institution. Current agreements are for the purposes of this analysis alone and as such new approval would be required. Requests for Data Sharing should be directed to <information.guardian@phc.ox.ac.uk>. Such requests will be considered by all data holders involved in this collaboration.

Introduction {#sec008}
============

Treatment of hypertension results in significant reductions in risk of subsequent cardiovascular disease \[[@pmed.1002389.ref001],[@pmed.1002389.ref002]\]. Despite strong evidence for such treatment, international epidemiological studies suggest that many people remain suboptimally controlled \[[@pmed.1002389.ref003]\]. Self-monitoring of blood pressure (BP), where individuals measure their own blood pressure, usually in a home environment, can improve BP control and is an increasingly common part of hypertension management. Such monitoring can be accompanied by additional support such as from a nurse or pharmacist \[[@pmed.1002389.ref004]\].

Self-monitoring is well tolerated by patients and has been shown to be a better predictor of end organ damage than clinic measurement \[[@pmed.1002389.ref005]--[@pmed.1002389.ref008]\]. This is despite potential issues with quality control of self-measurement such as poor technique or withholding of results \[[@pmed.1002389.ref009],[@pmed.1002389.ref010]\]. The latter can be reduced to an extent by the use of telemonitoring \[[@pmed.1002389.ref011]\].

Previous meta-analyses have shown that self-monitoring reduces clinic BP by a small but significant amount compared to conventional care (around 4/1.5 mmHg) \[[@pmed.1002389.ref004],[@pmed.1002389.ref012]--[@pmed.1002389.ref014]\]. Analysis by Bray and colleagues suggested that when self-monitoring was accompanied by a co-intervention, participants were more likely to meet target BP, but it remains unclear which interventions are most effective and what specific populations (if any) should be targeted \[[@pmed.1002389.ref014]\].

The aim of this work was therefore to use individual patient data (IPD) from relevant trials to assess the effectiveness of BP self-monitoring on BP reduction and hypertension control, evaluating how best to utilise self-monitoring of BP and to determine which subpopulation is most likely to benefit.

Materials and methods {#sec009}
=====================

This study systematically reviewed the existing literature to identify randomised trials examining the efficacy of self-monitoring of BP compared to control. Authors of all eligible trials were approached for access to IPD. A protocol with detailed methods has been published previously \[[@pmed.1002389.ref015]\]. The methods used are summarised below.

Data sources and searches {#sec010}
-------------------------

Medline, Embase, and the Cochrane Library were searched for trials using BP self-monitoring in hypertensive patients ([S2 Fig](#pmed.1002389.s009){ref-type="supplementary-material"}; search date June 2016).

Study selection {#sec011}
---------------

Two reviewers (RM and KT) independently assessed the articles for eligibility and inclusion; disagreements were resolved by discussion. Randomised trials were eligible that recruited patients with hypertension being managed as outpatients using an intervention that included self-measurement of BP. Self-monitoring had to be without medical professional input (i.e., by patient with or without carer support) and using a validated monitor, with or without other co-interventions, and where a comparator group had no organised self-measurement of BP. Included studies were required to have involved at least 100 patients, followed up for at least 24 weeks, and to have been published since 2000. This was to ensure that self-monitoring equipment was likely to be relevant to contemporary medical management (i.e., automated oscillometric monitors). Relevant outcomes were systolic blood pressure (sBP) and/or diastolic blood pressure (dBP) measured in clinic, by researcher or by ambulatory measurement, and achievement of BP control.

Data extraction and quality assessment {#sec012}
--------------------------------------

Authors whose trials met the inclusion criteria were approached for provision of IPD including demographic details, comorbidities, antihypertensive medications, lifestyle factors, and BP end points (clinic and/or ambulatory). Study-level data were extracted where available from published articles and checked by the original authors. In particular, any co-interventions were carefully documented and prospectively allocated to 1 of 4 levels of interventional support based on a previous classification \[[@pmed.1002389.ref004]\] ([S1 Table](#pmed.1002389.s003){ref-type="supplementary-material"}).

Study quality was assessed in terms of potential bias from randomisation, blinding, outcome assessment, and method of analysis using an adaptation of the Cochrane tool \[[@pmed.1002389.ref016]\].

Original data were kept on a secure server and assembled in a consistent format for all trials. Three researchers (KT, RM, and JS) cross-checked trial details, summary measures, major outcomes, and definitions against published articles. Any apparent inconsistencies were checked with the original trial authors. Overall ethical approval was not required as this study does not include identifiable data; collaborating groups gained individual approval where required for data sharing.

Data synthesis and analysis {#sec013}
---------------------------

A 2-stage IPD meta-analysis was conducted using linear regression for continuous outcomes and logistic regression for proportions, aggregated across studies by random-effects inverse variance methods. Intention-to-treat comparisons of outcomes between the self-monitoring and comparator arms were summarised with forest plots using the I-squared (*I*^2^) statistic for heterogeneity. Regression models were adjusted for age, sex, baseline clinic BP, and diabetic status (the latter due to the lower BP target generally used in a diabetic population).

The primary outcomes were change in sBP and dBP at 12 months and likelihood of uncontrolled BP below target at 12 months (control as defined by each trial). Analyses are reported in subgroups, by pre-specified level of self-monitoring intervention as described in [Table 1](#pmed.1002389.t001){ref-type="table"} and in the published protocol \[[@pmed.1002389.ref015]\].

10.1371/journal.pmed.1002389.t001

###### Characteristics of the included studies.

![](pmed.1002389.t001){#pmed.1002389.t001g}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Lead author(s) \[Ref\]\                                Study        Setting                                         Self-monitoring                                                                             Number of readings / session   Co-interventions                                                                                                    Pre-defined level   Comparison                                             Home target (mmHg)                 Clinic target (mmHg)               Baseline BP ±SD mmHg   No. randomised         Data available   No. 6M   No. 12M                                    No. 18M
  Country, Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  ------------------------------------------------------ ------------ ----------------------------------------------- ------------------------------------------------------------------------------------------- ------------------------------ ------------------------------------------------------------------------------------------------------------------- ------------------- ------------------------------------------------------ ---------------------------------- ---------------------------------- ---------------------- ---------------------- ---------------- -------- ------------------------------------------ ---------
  **Halme/ Kantola** \[[@pmed.1002389.ref041]\]\         HOMER        Primary care                                    Daily for 1 week every 2 months                                                             2                              None                                                                                                                **1**               Usual care                                             135/80                             140/85                             157/93±18/8            269                    231              170      N/A                                        N/A
  **Finland, 2005**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  **McManus** \[[@pmed.1002389.ref024]\]\                TASMINH      Primary care                                    Monthly in GP practice waiting room                                                         2                              None                                                                                                                **1**               Usual care                                             140/85\                            140/85\                            156/88±15/7            441                    440              413      401                                        N/A
  **UK 2005**                                                                                                                                                                                                                                                                                                                                                                                                                                   140/80 DM                          140/80 DM                                                                                                                                             

  **Bosworth** \[[@pmed.1002389.ref026]\]\               HINTS        Primary care                                    3 days per week                                                                             1                              Behavioural intervention                                                                                            **3**               Usual care                                             135/85\                            140/90\                            129/77±18/13           593                    591              535      523                                        N/A
  **US, 2007**                                                                                                                                                                                                                                                                                                                                                                                                                                  135/80 DM                          135/80 DM                                                                                                                                             

  Or meds management                                     **4**        130/78±19/14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Or both                                                **4**        128/77±19/13                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  **Verberk** \[[@pmed.1002389.ref025]\]\                HOMERUS      Primary care and outpatients                    1 week per month, then 1 week every 2 months                                                3                              None                                                                                                                **1**               Usual care with monthly clinic visits then 2 monthly   140/90                             140/90                             164/96±17/10           517                    517              N/A      434                                        N/A
  **Netherlands, 2007**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  **Green** \[[@pmed.1002389.ref042]\]\                  eBP          Primary care and outpatients                    2 days per week                                                                             2                              Website and email                                                                                                   **2**               Usual care                                             135/85                             140/90                             151/89±12/9            778                    778              N/A      730                                        N/A
  **US, 2008**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  +/- web-based pharmacist management                    **4**        151/89±12/9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  **Bosworth** \[[@pmed.1002389.ref027]\]\               TCYB         Primary care                                    3 days per week                                                                             1                              None                                                                                                                **1**               Usual care                                             135/85                             140/90                             125/71±16/10           636 (476 applicable)   446              383      350                                        324
  **US, 2009**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Or behavioural interventions, education, and support   **4**        130/80 DM                                       130/80 DM                                                                                   125/71±18/11                                                                                                                                                                                                                                                                                                                                                                                                           

  **Parati & Omboni** \[[@pmed.1002389.ref033]\]\        TeleBPcare   Primary Care                                    3 days per week                                                                             2                              Telemonitoring                                                                                                      **2**               Usual care                                             135/85                             140/90                             146/88±12/8            329                    298              298      N/A                                        N/A
  **Italy, 2009**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  **Godwin** \[[@pmed.1002389.ref043]\]\                              Primary Care                                    At least weekly                                                                             1                              None                                                                                                                **1**               Usual care                                             135/85                             140/90                             144/81±18/11           552                    458              458      458                                        N/A
  **Canada, 2010**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  **Earle** \[[@pmed.1002389.ref023]\]\                               Community (recruited through a hospital site)   Weekly                                                                                      1                              Blood glucose testing, text/app system with feedback from clinicians                                                **4**               Usual care                                             140/90                             140/90                             131/77±17/10           137                    126              126      N/A                                        N/A
  **UK, 2010**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **McManus** \[[@pmed.1002389.ref036]\]\                TASMINH2     Primary care                                    Daily for the first week of each month                                                      2                              Telemonitoring and self- titration                                                                                  **3**               Usual care                                             130/85\                            140/90\                            152/85±12/9            527                    527              480      480                                        N/A
  **UK, 2010**                                                                                                                                                                                                                                                                                                                                                                                                                                  130/75 DM                          140/80 DM                                                                                                                                             

  **Hebert** \[[@pmed.1002389.ref040]\]\                              Outpatients and primary care                    Variable                                                                                    Not clear                      None                                                                                                                **1**               Usual care                                                                                140/90                             153/86 16/13           416                    416              N/A      N/A                                        286
  **US, 2011**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Or nurse support                                       **4**        130/80DM                                        153/86 18/13                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  **Wakefield** \[[@pmed.1002389.ref031]\]\                           Primary care                                    Daily                                                                                       1                              Low-intensity management algorithm                                                                                  **2**               Usual care                                             135/85                             135/85                             135/72±18/11           302                    300              268      261[\*](#t001fn002){ref-type="table-fn"}   N/A
  **US, 2011**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  High-intensity algorithm                               **3**        130/80 DM                                       130/80 DM                                                                                   136/74±19/11                                                                                                                                                                                                                                                                                                                                                                                                           

  **Bove** \[[@pmed.1002389.ref044]\]\                   HTN          Primary care and outpatients                    2 days per week                                                                             Not clear                      Telemonitoring                                                                                                      **2**               Usual care                                                                                140/90                             155/88±15/11           241                    235              202      N/A                                        N/A
  **US, 2013**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **Kerry** \[[@pmed.1002389.ref039]\]\                               Community (recruited from stroke services)      Daily in week 1, then 1 day per week                                                        3                              Nurse-led telephone support                                                                                         **2**               Usual care                                             130/80                             140/85                             138/74±21/12           381                    381              352      334                                        N/A
  **UK, 2013**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **Magid** \[[@pmed.1002389.ref050]\]\                               Primary care                                    3 days per week                                                                             1                              Patient education and BP reporting; or patient education, BP reporting, and pharmacist management                   **4**               Usual care                                             135/85\                            140/90\                            147/15±89/10           338                    326              326      N/A                                        N/A
  **US, 2013**                                                                                                                                                                                                                                                                                                                                                                                                                                  125/75 DM/CKD                      130/80 DM/ CKD                                                                                                                                        

  **Margolis** \[[@pmed.1002389.ref037]\]\               Hyperlink    Primary care                                    3 days per week                                                                             2                              Telemonitoring and pharmacist management                                                                            **4**               Usual care                                             135/85\                            140/90\                            148/85±13/12           450                    450              403      388                                        370
  **US, 2013**                                                                                                                                                                                                                                                                                                                                                                                                                                  125/75 DM/CKD                      130/80 DM/CKD                                                                                                                                         

  **McKinstry** \[[@pmed.1002389.ref045]\]\              HITS         Primary care                                    Daily in week 1, then at least 1 day per week thereafter                                    2                              Optional automated telemonitoring                                                                                   **2**               Usual care                                             135/85                             140/90                             153/91±15/11           401                    401              374      N/A                                        N/A
  **UK, 2013**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **Parati** \[[@pmed.1002389.ref032]\]\                 TeleBPMET    Primary care                                    3 days per week                                                                             2                              Telemonitoring                                                                                                      **2**               Usual care                                             135/85                             140/90                             147/90±12/8            252                    182              181      179                                        N/A
  **Italy, 2013**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  **Green** \[[@pmed.1002389.ref051]\]\                  eCare                                                        At least 1 day per week for 2 months, then 1 day per fortnight for 2 months, then monthly   2                              Dietician with BP plan and visits (weekly for 2 months, fortnightly for 2 months, then monthly)                     **4**               Usual care                                             135/85                             140/90                             150/92±12/9            101                    101              90       N/A                                        N/A
  **US, 2014**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **Leiva** \[[@pmed.1002389.ref046]\]\                  Adherencia   Primary care                                    Weekly, with morning and afternoon readings                                                 3                              Motivational interview, pillbox reminder, family support, BP and medication reminder form, and pharmacist review    **3**               Usual care                                             135/85                             140/90 and 130/80 for DM or CKD    156/84±15/11           221                    215              N/A      215                                        N/A
  **Spain, 2014**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  **McManus** \[[@pmed.1002389.ref035]\]\                TASMIN-SR    Primary care                                    Daily for the first week of each month                                                      2                              Self-management                                                                                                     **3**               Usual care                                             120/75                             130/80 ST                          144/80±13/10           552                    450              439      450                                        N/A
  **UK 2014**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  **Ogedegbe** \[[@pmed.1002389.ref034]\]\               CAATCH       Primary care                                    3 days per week                                                                             1                              Education, lifestyle, and behavioural support                                                                       **3**               Usual care                                                                                                                   151/91±17/10           1,039                  997              610      691                                        N/A
  **US, 2014**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **Stewart** \[[@pmed.1002389.ref048]\]\                HAPPy        Primary care                                    Several readings per week                                                                   1                              Pharmacist management with motivational interviewing, medication review, education, and optional refill reminders   **4**               Usual care                                             140/90 and 130/80 for DM and CKD   140/90 and 130/80 for DM and CKD   141/84±20/11           395                    391              351      N/A                                        N/A
  **Australia, 2014**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  **Yi** \[[@pmed.1002389.ref047]\]\                                  Primary care                                    As prescribed by their doctor                                                               Variable                       Educational material on hypertension                                                                                **1**               Usual care                                             140/90 or 130/80 DM or CKD         140/90 or 130/80 DM or CKD         152/83±16/11           900                    828              529      N/A                                        N/A
  **US, 2015**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **Parati** (unpublished study)\                        AUPRES       Primary care                                    3 days per week                                                                             3                                                                                                                                                  **1**               Usual care                                             135/85                             140/90                             154/95±15/8            407                    407              407      407                                        407
  **Italy**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Summary information of included studies. Differences between number randomised and data available for Godwin (2010) and McManus (2014) are due to the use of complete case data only. The difference observed in Bosworth (2009) results from the removal of the behavioural intervention arm and patients with missing baseline BP data. Abbreviations: BP, blood pressure; CKD, chronic kidney disease; DM, diabetes mellitus; GP, general practitioner; M, months; ST, self-tested BP.

\*Participants self-monitored for 6 months; follow-up data collected at 12 months.

Subgroup analyses examined the effect of self-monitoring on BP mean and control by age, sex, baseline sBP, the presence and number of antihypertensive medications prescribed, and comorbidities (myocardial infarction \[MI\], stroke, diabetes mellitus \[DM\], chronic kidney disease \[CKD\], and obesity \[defined as a body mass index (BMI) ≥ 30 kg/m^2^\]). All subgroup analyses were adjusted for age, sex, baseline clinic BP, level of intervention, and individual study (contributing to each analysis).

Sensitivity analyses included incorporation of aggregate data from studies that did not contribute IPD \[[@pmed.1002389.ref017]--[@pmed.1002389.ref023]\], exclusion of individual patients for whom a lower home BP target was not used (due to study design or the presence of comorbidities such as diabetes) \[[@pmed.1002389.ref024]--[@pmed.1002389.ref027]\], influence of BP inclusion criteria (clinic or ambulatory) from ambulatory outcome studies, different assumptions regarding BP of patients lost to follow-up (controlled or uncontrolled), and influence of adjusting for medication changes (in those studies which recorded changes in medication). Finally, the influence of each study on the overall results was assessed using an influence analysis. Egger's test for funnel plot asymmetry was applied to consider possible publication bias ([S21 Fig](#pmed.1002389.s028){ref-type="supplementary-material"}) \[[@pmed.1002389.ref028]\].

There were no deviations from the protocol \[[@pmed.1002389.ref015]\]. Five post-hoc analyses were undertaken: firstly, an additional subgroup analysis was carried out (resistant hypertension \[defined as BP \> 140/90 mmHg and 3 medications at baseline or any BP level and 4 or more medications at baseline\]); secondly, the distribution of baseline antihypertensive medications was compared in patients with and without a history of stroke using Pearson's chi-squared; thirdly, the effectiveness of self-monitoring in stroke was assessed controlling for the number of baseline medications; fourthly, the influence of blinding was assessed; and finally, sBP was plotted against medication changes.

Statistical software and presentation {#sec014}
-------------------------------------

All analyses were conducted using STATA version 13.1 (MP parallel edition, StataCorp, College Station, Texas, USA), using the ipdmetan package \[[@pmed.1002389.ref029]\]. Data are presented as proportions of the total study population, means with standard deviation or relative risk (RR) with 95% confidence intervals unless otherwise stated.

Results {#sec015}
=======

Of 2,846 unique studies from the combined searches, 132 were assessed in full and 36 studies were deemed potentially eligible ([S1 Fig](#pmed.1002389.s008){ref-type="supplementary-material"}). One study which would otherwise have been eligible was excluded because the comparator group used ambulatory monitoring to guide treatment, a control intervention that had not been anticipated in the protocol but which was not comparable to any other included studies \[[@pmed.1002389.ref030]\]. Of the 36 potentially eligible studies, 19 had published data at 12 months, the primary outcome. Authors from 24 of the potentially eligible studies provided IPD, with 1 group submitting additional data from an unpublished study. These 25 studies were published from 2005--2014, were conducted in North America and Europe (11 United States; 6 United Kingdom; 3 Italy; 1 each from the Netherlands, Australia, Spain, Finland, and Canada), and included a wide range of self-monitoring protocols, co-interventions, and populations ([Table 1](#pmed.1002389.t001){ref-type="table"}) \[[@pmed.1002389.ref023]--[@pmed.1002389.ref027],[@pmed.1002389.ref031]--[@pmed.1002389.ref048]\]. Authors from the remaining 12 studies were either unable to provide IPD (2 studies) or did not respond to the request for data (10 studies). Four studies which followed up patients for 12 months did not provide IPD, so that data for the primary outcome were available from 15/19 studies (7,138/8,292 \[86%\], of potential participants) ([S2 Table](#pmed.1002389.s004){ref-type="supplementary-material"}) \[[@pmed.1002389.ref017],[@pmed.1002389.ref018],[@pmed.1002389.ref022],[@pmed.1002389.ref049]\]. A total of 838 patients (12%) were lost to follow-up across all included studies, and a further 227 patients from the potentially available studies were lost to follow-up, leaving 6,300/7,227 patients (87%) for inclusion in the final analysis of the primary outcome (12 months follow-up).

Overall, the information from the included trials was judged to be at low risk of bias: most studies used computerised generation of randomisation sequences (23/25, 92%), appropriate allocation concealment (24/25, 96%), and all used an intention-to-treat approach with either multiple imputation for missing data or analysis of complete cases. Most studies (19/25, 76%) followed up more than 80% of participants, but only 12/25 (48%) used blinded assessment of outcome ([S3 Table](#pmed.1002389.s005){ref-type="supplementary-material"}). An influence analysis assessed the impact of each individual study on the overall results. Included studies were predominantly publically funded ([S4 Table](#pmed.1002389.s006){ref-type="supplementary-material"}).

Clinic BP {#sec016}
---------

Overall, self-monitoring was associated with reduced clinic sBP between baseline and 12-months follow-up compared to usual care (systolic −3.2 mmHg, 95% CI −4.9 to −1.6 mmHg) ([Fig 1](#pmed.1002389.g001){ref-type="fig"}). Significant heterogeneity was present between studies: *I*^2^ = 76%, *P* \< 0.001. Self-monitoring was also associated with reduced dBP at 12-months follow-up (diastolic −1.5 mmHg, 95% CI −2.2 to −0.8 mmHg) and significant heterogeneity remained (*I*^2^ = 62%, *P* \< 0.001) ([Fig 2](#pmed.1002389.g002){ref-type="fig"}). Similar reductions in BP were seen after 6-months follow-up, but the point estimates after 18-months follow-up were smaller, albeit from only 5 studies ([S3](#pmed.1002389.s010){ref-type="supplementary-material"}, [S4](#pmed.1002389.s011){ref-type="supplementary-material"}, [S6](#pmed.1002389.s013){ref-type="supplementary-material"} and [S7](#pmed.1002389.s014){ref-type="supplementary-material"} Figs).

![Impact of self-monitoring of BP on clinic sBP according to level of co-intervention support at 12 months (15 studies).\
Change in sBP adjusted for age, sex, baseline clinic BP, and history of diabetes. The trials are grouped into the 4 levels of intervention, and *I*^2^ and *P* values are shown for each level of intervention and for the overall analysis. Effect of self-monitoring on clinic sBP at 6 and 18 months are shown in [S3](#pmed.1002389.s010){ref-type="supplementary-material"} and [S6](#pmed.1002389.s013){ref-type="supplementary-material"} Figs, respectively. Wakefield's study participants self-monitored for 6 months; follow-up continued to 12 months. Abbreviations: BP, blood pressure; sBP, systolic blood pressure.](pmed.1002389.g001){#pmed.1002389.g001}

![Impact of self-monitoring of BP on clinic dBP according to level of co-intervention support at 12 months (15 studies).\
Change in dBP adjusted for age, sex, baseline clinic BP, and history of diabetes. The trials are grouped into the 4 levels of intervention, and *I*^2^ and *P* values are shown for each level of intervention and for the overall analysis. Effect of self-monitoring on clinic dBP at 6 and 18 months are shown in [S4](#pmed.1002389.s011){ref-type="supplementary-material"} and [S7](#pmed.1002389.s014){ref-type="supplementary-material"} Figs, respectively. Wakefield's participants self-monitored for 6 months; follow-up continued to 12 months. Abbreviations: BP, blood pressure; dBP, diastolic blood pressure.](pmed.1002389.g002){#pmed.1002389.g002}

Clinic BP control {#sec017}
-----------------

Clinic BP control was improved at 12-months follow-up (RR of uncontrolled BP 0.7 \[95% CI 0.56 to 0.86\]) again with significant heterogeneity between groups ([Fig 3](#pmed.1002389.g003){ref-type="fig"}). Similar results were seen at 6 and 18 months ([S5](#pmed.1002389.s012){ref-type="supplementary-material"} and [S8](#pmed.1002389.s015){ref-type="supplementary-material"} Figs, respectively).

![Impact of self-monitoring of BP on the RR of uncontrolled BP at 12 months according to level of co-intervention support (15 studies).\
RR of uncontrolled BP adjusted for age, sex, baseline clinic BP, and history of diabetes. The trials are grouped into the 4 levels of intervention, and *I*^2^ and *P* values are shown for each level of intervention and for the overall analysis. The effect of self-monitoring on the RR of BP at 6 and 18 months are displayed in [S5](#pmed.1002389.s012){ref-type="supplementary-material"} and [S8](#pmed.1002389.s015){ref-type="supplementary-material"} Figs, respectively. Wakefield study participants self-monitored for 6 months; follow-up continued to 12 months. Abbreviations: BP, blood pressure; RR, relative risk.](pmed.1002389.g003){#pmed.1002389.g003}

Intensity of co-intervention {#sec018}
----------------------------

The reductions in clinic sBP varied with different levels of intervention: level 1 (with no co-intervention) −1.0 mmHg, \[95% CI −3.3 to 1.2 mmHg\]; level 4 (personal support throughout the trial) −6.1 mmHg, \[95% CI −9.0 to −3.2 mmHg\] ([Fig 1](#pmed.1002389.g001){ref-type="fig"}) (heterogeneity in outcome between different levels of intervention *P* \< 0.001). Within predefined categories of intensity of co-intervention, significant heterogeneity remained, apart from within level 2.

A similar pattern of reductions was seen in dBP: level 1 (with no co-intervention) −1.1 mmHg, \[95% CI −2.4 to 0.2 mmHg\]; level 4 (personal support throughout the trial) −2.3 mmHg, \[95% CI −4.0 to −0.6 mmHg\] ([Fig 2](#pmed.1002389.g002){ref-type="fig"}) (heterogeneity in outcome between different levels of intervention *P* \< 0.001). Within predefined categories of intensity of co-intervention, significant heterogeneity remained in levels 1 and 4.

BP control (defined according to individual study targets, [Table 1](#pmed.1002389.t001){ref-type="table"}) at 12 months also differed by level of intensity. The RR of having uncontrolled BP with a self-monitoring intervention at 12 months varied from level 1 (RR 1.0, 95% CI 0.7 to 1.4) to level 4 (RR 0.4, 95% CI 0.3 to 0.6) ([Fig 3](#pmed.1002389.g003){ref-type="fig"}) (heterogeneity between levels of intervention *P* \< 0.001). Heterogeneity within levels of intervention in this analysis was low for levels 2 and 4 of co-intervention, although the *I*^*2*^ remained above 50% for level 1. Similar results were seen at 6-months follow-up (21 studies) and at 18-months follow-up (5 studies) ([S5](#pmed.1002389.s012){ref-type="supplementary-material"} and [S8](#pmed.1002389.s015){ref-type="supplementary-material"} Figs, respectively).

Ambulatory BP {#sec019}
-------------

Four studies had data at 12 months using ambulatory BP as the outcome (1,478 participants); these were studies with no co-intervention (level 1; *n* = 3) or automated feedback only (level 2; *n* = 1). No change was seen in ambulatory sBP associated with self-monitoring (1.1 mmHg \[−0.3, 2.5\]) ([Fig 4](#pmed.1002389.g004){ref-type="fig"}) or ambulatory dBP (0.8 mmHg \[−0.2, 1.9\]), and there was no significant heterogeneity between studies in either case ([Fig 5](#pmed.1002389.g005){ref-type="fig"}). At 6 months, data were available for 5 studies with no difference seen in ambulatory sBP (−1.0 mmHg \[−2.8, 0.9\]) or dBP (−0.4 mmHg \[−1.6, 0.8\]) ([S9](#pmed.1002389.s016){ref-type="supplementary-material"} and [S10](#pmed.1002389.s017){ref-type="supplementary-material"} Figs, respectively). The additional study, which used a level 3--intensity intervention, increased heterogeneity as it had a significant outcome.

![Impact of self-monitoring of BP on clinic and ambulatory sBP at 12 months (4 studies).\
These 4 studies used both clinic and ambulatory BP as endpoints and so are presented in addition to the overall results in [Fig 1](#pmed.1002389.g001){ref-type="fig"}, which are for clinic BP alone (including these studies). Change in sBP adjusted for age, sex, baseline clinic BP, history of diabetes, and level of intervention. Effect of self-monitoring on systolic clinic and ambulatory BP at 6 months is in [S9 Fig](#pmed.1002389.s016){ref-type="supplementary-material"}. Abbreviations: BP, blood pressure; sBP, systolic blood pressure.](pmed.1002389.g004){#pmed.1002389.g004}

![Impact of self-monitoring of BP on clinic and ambulatory dBP at 12 months (4 studies).\
These 4 studies used both clinic and ambulatory BP as endpoints and so are presented in addition to the overall results in [Fig 1](#pmed.1002389.g001){ref-type="fig"}, which are for clinic BP alone (including these studies). Change in dBP adjusted for age, sex, baseline clinic BP, history of diabetes, and level of intervention. Effect of self-monitoring on diastolic clinic and ambulatory BP at 6 months is in [S10 Fig](#pmed.1002389.s017){ref-type="supplementary-material"}. Abbreviations: BP, blood pressure; dBP, diastolic blood pressure.](pmed.1002389.g005){#pmed.1002389.g005}

No ambulatory data were available at 18 months.

Subgroup analysis {#sec020}
-----------------

Subgroup analyses using data from 12-months follow-up showed little difference in either reduction of systolic or diastolic clinic BP or likelihood of uncontrolled BP depending on history of MI or presence of CKD or diabetes (Figs [6](#pmed.1002389.g006){ref-type="fig"}, [7](#pmed.1002389.g007){ref-type="fig"} and [8](#pmed.1002389.g008){ref-type="fig"}) (*I*^2^ ≤ 20% for all subgroups).

![Impact of self-monitoring of BP on clinic sBP at 12 months according to prespecified subgroups (15 studies).\
Obesity defined as BMI ≥ 30 kg/m^2^. Change in sBP at 12 months adjusted for age, sex, baseline clinic BP, level of intervention, and studies contributing patient data. Abbreviations: BMI, body mass index; BP, blood pressure; CKD, chronic kidney disease; MI, myocardial infarction; sBP, systolic blood pressure.](pmed.1002389.g006){#pmed.1002389.g006}

![Impact of self-monitoring of BP on clinic dBP at 12 months according to prespecified subgroups (15 studies).\
Obesity defined as BMI ≥ 30 kg/m^2^. Change in dBP at 12 months adjusted for age, sex, baseline clinic BP, level of intervention, and studies contributing patient data. Abbreviations: BMI, body mass index; BP, blood pressure; CKD, chronic kidney disease; dBP, diastolic blood pressure; MI, myocardial infarction.](pmed.1002389.g007){#pmed.1002389.g007}

![Impact of self-monitoring of BP on the RR of uncontrolled BP at 12 months according to prespecified subgroups (15 studies).\
Obesity defined as BMI ≥ 30 kg/m^2^. RR of uncontrolled BP at 12 months adjusted for age, sex, baseline clinic BP, level of intervention, and studies contributing patient data. Abbreviations: BMI, body mass index; BP, blood pressure; CKD, chronic kidney disease; MI, myocardial infarction; RR, risk ratio; sBP, systolic blood pressure.](pmed.1002389.g008){#pmed.1002389.g008}

However, a history of stroke was associated with a reduced effectiveness of self-monitoring in terms of clinic sBP lowering (*I*^2^ = 77%, *P* = 0.04), though this difference was not observed for dBP or maintained in the likelihood of control analysis (RR *I*^2^ = 42%, *P* = 0.19). Post-hoc analyses showed that the distribution of number of medications between stroke and non-stroke patients was similar ([S5 Table](#pmed.1002389.s007){ref-type="supplementary-material"}), and adjusting for baseline medication use did not explain the lack of effectiveness in patients with stroke. There was moderate heterogeneity between age groups for the effect of self-monitoring on systolic and diastolic clinic BP (*I*^2^ = 31%, *P* = 0.20 and *I*^2^ = 33, *P* = 0.19, respectively) but not in the likelihood of uncontrolled BP (*I*^2^ = 0.0%, *P* = 0.60). Considering the effect of obesity, there was no difference in the effect on systolic clinic BP reduction (*I*^2^ = 0, *P* = 0.72) but there was some evidence of heterogeneity of effect for dBP (*I*^2^ = 63, *P* = 0.10) and the risk of uncontrolled BP (*I*^2^ = 61%, *P* = 0.11).

Fewer baseline antihypertensive medications were associated with larger reductions of BP and better control (Figs [6](#pmed.1002389.g006){ref-type="fig"}--[8](#pmed.1002389.g008){ref-type="fig"}). Post-hoc analyses, comparing those with resistant hypertension to those without, suggested that self-monitoring was less effective at achieving BP control in the former (RR of uncontrolled BP = 0.62, 95% CI 0.54--0.71 \[non-resistant hypertension\] versus RR of uncontrolled BP = 0.94, 95% CI 0.65--1.36 \[resistant hypertension\], *I*^2^ = 76%, *P* = 0.04). Similarly, the post-hoc analysis plotting change in sBP against medication changes was consistent with the hypothesis that self-monitoring interventions resulted in BP decreases via increases in prescribed medication ([S22 Fig](#pmed.1002389.s029){ref-type="supplementary-material"}).

Sensitivity analysis {#sec021}
--------------------

Inclusion of aggregate data for clinic BP at 12 months from the 4 eligible studies that did not contribute IPD ([S2 Table](#pmed.1002389.s004){ref-type="supplementary-material"}) and exclusion of studies that did not use a lower home BP threshold did not materially change the results ([S11](#pmed.1002389.s018){ref-type="supplementary-material"} and [S12](#pmed.1002389.s019){ref-type="supplementary-material"} Figs). The exclusion of studies that randomised on the basis of ambulatory BP monitoring (ABPM) or studies that randomised on clinic BP did not change the impact of clinic or ambulatory measurement of sBP at 12 months ([S13](#pmed.1002389.s020){ref-type="supplementary-material"} and [S14](#pmed.1002389.s021){ref-type="supplementary-material"} Figs). Assuming patients lost to follow-up had uncontrolled BP attenuated the results, whereas assuming that they had controlled BP accentuated them ([S15](#pmed.1002389.s022){ref-type="supplementary-material"} and [S16](#pmed.1002389.s023){ref-type="supplementary-material"} Figs, respectively). Exclusion of patients with controlled BP at baseline also accentuated the results ([S17 Fig](#pmed.1002389.s024){ref-type="supplementary-material"}). A post-hoc comparison of studies with blinded outcome (2,829 patients) versus unblinded (3,257 patients) showed that blinding was associated with a reduced point estimate for the change in sBP at 12 months in those studies examining higher-level interventions, albeit with overlapping confidence intervals (level 1 & 2 intervention studies: −1.51, 95% CI −4.06 to 1.04 \[blinded\] versus −0.83, 95% CI −2.38 to 0.73 \[unblinded\]; level 3 & 4 intervention studies: −4.67, 95% CI −7.51 to −1.84 \[blinded\] versus −6.16, 95% CI −9.36 to −2.95 \[unblinded\]).

Where studies had measured changes in antihypertensive medication over time, there was evidence of attenuation of the change in sBP when the analysis was adjusted for change in medication ([S18](#pmed.1002389.s025){ref-type="supplementary-material"} and [S19](#pmed.1002389.s026){ref-type="supplementary-material"} Figs). The influence analysis did not suggest that any one study was materially influencing the results ([S20 Fig](#pmed.1002389.s027){ref-type="supplementary-material"} and Egger's test found no evidence of asymmetry in the funnel plot (*P* = 0.9, [S21 Fig](#pmed.1002389.s028){ref-type="supplementary-material"}).

Discussion {#sec022}
==========

Main findings {#sec023}
-------------

Using IPD from 25 studies totalling 10,487 patients, this meta-analysis provides strong evidence that the degree of BP lowering is related to the intensity of the co-intervention (i.e., additional support) combined with self-monitoring, with little or no effect from self-monitoring alone.

These results held whether systolic or diastolic clinic BP or clinic BP control were assessed and were consistent at both 6 and 12 months. No data were available from studies with intensive co-interventions which used ambulatory BP monitoring to measure outcomes at 12 months or longer, and those with little or no co-intervention showed similar effects to the clinic BP data (no effect in either case). There was a suspicion of attenuation of the effect of self-monitoring in the few studies to date that have followed up patients for longer than 1 year but data were sparse. Future research might be directed towards longer studies with ambulatory BP measurement (or other measurements to reduce the white coat effect) for outcomes. Self-monitoring appeared most effective at lowering BP in people on fewer BP medications at baseline, and there was a suggestion of a greater effect with higher BP---provided BP was not 170 mmHg or above. Analyses considering those with apparent resistant hypertension at baseline suggested that self-monitoring works less well in this group, but this analysis was not prespecified, could not take into account dose of antihypertensive medication, and should be interpreted with caution. In terms of comorbidities, the effects of self-monitoring were similar whether or not an individual had a history of MI, diabetes, or CKD. In people with previous stroke, there may be a reduced effect of self-monitoring but this did not reflect more intensive treatment prior to randomisation.

Strengths and weaknesses {#sec024}
------------------------

To our knowledge, this is the first analysis of self-monitoring of BP to use IPD from a wide range of self-monitoring trials from North America, Australia, and Europe and including both specialist and primary care settings. IPD allowed for standardised adjustment of outcomes and sufficient power to detect differences between subgroups.

An important issue in IPD analysis is selection of studies. The BP---SMART collaboration has gained access to a large number of datasets; nevertheless, some studies were not available due to unavailability of data or lack of response. Despite this, only 4 studies eligible for the primary outcome (14% of available patient data) were unable to provide data, and sensitivity analyses suggested no material change in the results when the published aggregate data from these studies were included.

Quality of included studies was adequate in terms of randomisation sequences, appropriate allocation concealment, and analyses. Follow-up was high for most studies but only half used blinded assessment of outcome. However, a post-hoc sensitivity analysis showed no difference in results from blinding, perhaps because in most studies BP was assessed using automated monitors reducing the chance of bias.

Despite the use of IPD and the division of studies into subgroups, significant heterogeneity remained, which limited the ability to do meta-analysis. However, this does not negate the conclusion that the evidence for both BP reduction and control is stronger for higher-intensity interventions and weak for self-monitoring alone. The hypothesis that effect would vary with level of intervention was prespecified and the categorisation of studies into 4 levels of intervention was agreed to by all study investigators before results were available.

Whilst all included studies compared self-monitoring of BP to control groups without self-monitoring, inevitably different investigators used different protocols and therefore studies differed in inclusion criteria, self-monitoring regime, and target BPs. These issues could at least in part explain the remaining heterogeneity between studies. The exclusion of studies which did not use lower BP targets for self-monitored BP did not change the results, but even IPD analysis is unable to take differences between studies entirely into account and this may be reflected in the heterogeneity which remained. Significance tests should be interpreted with caution when, as in Figs [6](#pmed.1002389.g006){ref-type="fig"} and [7](#pmed.1002389.g007){ref-type="fig"}, multiple coequal exposures are under test; however, the 3 *P* values ≤ 5% for heterogeneity across these 18 tests are unlikely to be all due to chance alone and the tests were prespecified.

Most outcome data were based on clinic measurement of BP, which is what was used by the majority of trials of outcome of hypertension treatment \[[@pmed.1002389.ref001]\]. Ambulatory monitoring might reduce any attenuation to the white coat effect from repeated habituation to measurement but, whilst 6 studies used ambulatory BP as an outcome \[[@pmed.1002389.ref025],[@pmed.1002389.ref032],[@pmed.1002389.ref033],[@pmed.1002389.ref043],[@pmed.1002389.ref045]\] (including 1 unpublished study), all but 1 of these used less intensive or no co-interventions. The single intensive study with an ambulatory outcome had data to 6 months and a positive result, whereas the remaining 4 studies showed no impact on ambulatory BP in common with the pooled results for clinic BP. Other studies have used multiple automated BP measurements in the clinic to assess habituation and have found no evidence that the BP differences are removed when the white coat effect is reduced, though further studies examining the effects of self-monitoring with intensive co-interventions on outcomes which reduce white coat effects are arguably needed \[[@pmed.1002389.ref036]\] \[[@pmed.1002389.ref035]\].

Even with IPD, issues such as loss to follow-up may be important. Included studies had rates of follow-up between 58% and 98% at 12 months with most studies following-up around 90%. In the main analysis, formal methods for handling missing data were not used since methods for imputation in IPD meta-analysis are in their infancy; however, the impact of each individual study on the overall results as assessed by the influence analysis suggests that factors such as differential follow-up between studies were unlikely to have affected the results \[[@pmed.1002389.ref052]\].

The outcomes included in this review are all related to BP. Whilst BP is directly related to stroke and coronary heart disease risk, it is nevertheless an intermediate outcome. Ideally, such hard outcomes would be directly measured in trials. However, because of relatively short follow-up and small numbers of participants, few included individual trials did so.

Comparison with the previous literature {#sec025}
---------------------------------------

There have been previous systematic reviews of trials of self-monitoring \[[@pmed.1002389.ref004],[@pmed.1002389.ref013],[@pmed.1002389.ref014],[@pmed.1002389.ref053]\], including those focussing on specific outcomes such as adherence \[[@pmed.1002389.ref054]\] or processes such as telemonitoring \[[@pmed.1002389.ref055]\], but all previous analyses have relied on summary statistics rather than IPD. Compared to the most recent and comprehensive summary data review, the current study has provided pooled estimates of the effect of self-monitoring with different levels of co-intervention, suggests that self-monitoring alone has little impact on BP, and provides new evidence that the level of BP reduction is related to the intensity of the co-intervention \[[@pmed.1002389.ref004]\].

Self-monitoring in the absence of such a co-intervention had little effect on BP. This is not to say that self-monitoring alone should be discouraged, for it brings other advantages both theoretical (better estimation of the underlying BP, increased self-efficacy for the patient) \[[@pmed.1002389.ref006]\] and practical (increased adherence, reduced need for monitoring within the clinic, and identification of white coat and masked hypertension) \[[@pmed.1002389.ref024],[@pmed.1002389.ref054]\]. These advantages are despite any potential inaccuracy caused by individuals not conforming to the recommended self-monitoring regime \[[@pmed.1002389.ref009],[@pmed.1002389.ref010]\].

Obese patients had similar BP reductions to non-obese individuals but greater chance of BP control, which does not reflect differences in mean BP. The findings concerning patients with previous stroke and resistant hypertension require some caution, particularly the latter which was a post-hoc analysis, but have not been previously described. In the case of stroke, the results do not appear to be due to baseline intensity of antihypertensive treatment and warrant further study as more data become available.

Meaning of the study {#sec026}
--------------------

Combining self-monitoring with increased collaboration between patient and either a nurse, physician, or pharmacist can result in important decreases in BP (6 mmHg systolic on average for the more intensive co-interventions) and improved control. The mechanisms for these reductions in BP could include lifestyle changes (no data available); increased adherence to medication (no data available) \[[@pmed.1002389.ref054]\]; or increased prescription of medications, i.e., overcoming clinical inertia (data available from 11 studies). In order to assess the impact of enhanced medication prescription, number of medication changes was plotted against changes in BP and showed that increased numbers of medication changes were weakly correlated with reduced BP ([S22 Fig](#pmed.1002389.s029){ref-type="supplementary-material"}). Whatever the mechanism, the literature suggests that a 6 mmHg reduction in sBP, as observed in higher-intensity interventions, would reduce subsequent stroke by more than 20% \[[@pmed.1002389.ref056]\]. Considering the content of such interventions is an important part of decision-making in the implementation of self-monitoring. [Table 1](#pmed.1002389.t001){ref-type="table"} and [S1 Table](#pmed.1002389.s003){ref-type="supplementary-material"} describe the key characteristics of effective interventions which depend on actively intervening in terms of medication titration and/or health behaviours. Much of the effect appears to be associated with one-to-one intervention combined with medication intensification. Self-monitoring can therefore facilitate significant improvements in BP level and control but should not necessarily be seen as reducing clinical input because clinical input within the co-interventions is often required for effective BP lowering.

The recent SPRINT trial results suggest that more intensive BP interventions are likely to be important in terms of morbidity and mortality \[[@pmed.1002389.ref057]\]. Increasing the level or intensity of intervention also increases the cost of an intervention, both directly to the health provider and also in terms of patients' time. Understanding the relative cost-effectiveness of the different co-interventions is likely to be important in deciding policy in this area and will require further work.

The effects appear to be independent of age, sex, and a range of comorbidities (such as MI, CKD, diabetes, and obesity), but there was a suggestion that people receiving less intensive antihypertensive treatment, and those with the highest BPs (up to 170 mmHg systolic), may have the most to gain, presumably because they are not already receiving sufficient doses of medication. Conversely, with resistant hypertension there appeared to be little effect from self-monitoring. Similar results for stroke should be interpreted cautiously and warrant further study.

The data presented appear to indicate a potential attenuation of the beneficial effects of self-monitoring over time (see [S6](#pmed.1002389.s013){ref-type="supplementary-material"}, [S7](#pmed.1002389.s014){ref-type="supplementary-material"} and [S8](#pmed.1002389.s015){ref-type="supplementary-material"} Figs). We believe that the key issue is a need for longer studies (at least 2 years, and preferably 5 years or more) that are accompanied by investigation of how best to administer a self-monitoring---based intervention in the long term, including whether it should be perhaps "topped up" with additional training over time.

Finally, we know from the individual trials that only a proportion of those with hypertension will be suitable for self-monitoring. Despite this, the numbers of people with hypertension and access to their own BP monitor are likely to be well into the tens of millions internationally and represent an important population to engage with \[[@pmed.1002389.ref058],[@pmed.1002389.ref059]\].

Future research {#sec027}
---------------

Several unanswered questions remain. Ultimately, trials including cardiovascular endpoints would provide the strongest evidence for self-monitoring in the management of hypertension but may not be appropriate given the strong evidence linking BP to outcome. Further consideration of self-monitoring in the presence of comorbidities seems warranted, particularly for stroke. Furthermore, this review has not included economic outcomes (available from 6 of the included studies) or quality of life measures (available in 8 of the included studies), and these outcomes form part of the next series of investigations for this collaboration.

Conclusions {#sec028}
-----------

Self-monitoring of BP combined with co-interventions involving individually tailored support lowers clinic BP but has little effect on its own. Self-monitoring supported by such co-interventions should be recommended as part of routine clinical practice in international guidelines and further research should determine the most cost-effective means of supporting implementation.

Supporting information {#sec029}
======================

###### PRISMA checklist.

(DOC)

###### 

Click here for additional data file.

###### The protocol paper published by the BMJ Open (available at <http://bmjopen.bmj.com/content/bmjopen/5/9/e008532.full.pdf>).

(PDF)
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Click here for additional data file.

###### Levels of self-monitoring intervention.

Levels used to describe the included self-monitoring interventions. \* 1:1 contact or support in this context refers to contact over and above that in usual care. Abbreviation: BP, blood pressure.

(DOCX)
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Click here for additional data file.

###### Studies not included in the IPD analysis.

\*Data were available from trials including 7,138/8,292 (86%) of patients randomised. ^+^Data at 6 months follow-up were available from 8,563/12,822 (67%) of patients randomised. Abbreviation: IPD, individual patient data.

(DOCX)
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Click here for additional data file.

###### Assessment of bias.

\*Due to the nature of the intervention, the participants in all studies were aware that they were in the self-monitoring group.

(DOCX)
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Click here for additional data file.

###### Funding provided to the included studies.

Table showing the funding of the included studies.

(DOCX)
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Click here for additional data file.

###### Distribution of baseline medications by history of stroke.

(DOCX)
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Click here for additional data file.

###### Flow diagram of the systematic search and selection of relevant studies.

Flow diagram of the systematic review and selection of studies for the IPD.

(DOCX)
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Click here for additional data file.

###### Example search strategy.

An example search from Medline.

(DOCX)

###### 

Click here for additional data file.

###### Impact of self-monitoring of BP on clinic sBP according to level of co-intervention support at 6 months (21 studies).

Change in sBP adjusted for age, sex, baseline clinic BP, and history of diabetes. Abbreviations: BP, blood pressure; sBP, systolic blood pressure.

(TIF)

###### 

Click here for additional data file.

###### Impact of self-monitoring of BP on clinic dBP according to level of co-intervention support at 6 months (21 studies).

Change in dBP adjusted for age, sex, baseline clinic BP, and history of diabetes. Abbreviations: BP, blood pressure; dBP, diastolic blood pressure.

(TIF)

###### 

Click here for additional data file.

###### Impact of self-monitoring of BP on the RR of uncontrolled BP at 6 months according to level of co-intervention support (21 studies).

RR of uncontrolled BP adjusted for age, sex, baseline clinic BP, and history of diabetes. Abbreviations: BP, blood pressure; RR, relative risk.

(TIF)

###### 

Click here for additional data file.

###### Impact of self-monitoring of BP on clinic sBP according to level of co-intervention support at 18 months (5 studies).

Change in sBP adjusted for age, sex, baseline clinic BP, and history of diabetes. Abbreviations: BP, blood pressure; sBP, systolic blood pressure.

(TIF)

###### 

Click here for additional data file.

###### Impact of self-monitoring of BP on clinic dBP according to level of co-intervention support at 18 months (5 studies).

Change in dBP adjusted for age, sex, baseline clinic BP, and history of diabetes. Abbreviations: BP, blood pressure; dBP, diastolic blood pressure.

(TIF)

###### 

Click here for additional data file.

###### Impact of self-monitoring of BP on the RR of uncontrolled BP at 18 months according to level of co-intervention support (5 studies).

RR of uncontrolled BP adjusted for age, sex, baseline clinic BP, and history of diabetes. Abbreviations: BP, blood pressure; RR, relative risk.

(TIF)

###### 

Click here for additional data file.

###### Impact of self-monitoring of BP on clinic and ambulatory sBP at 6 months.

Change in sBP adjusted for age, sex, baseline clinic BP, history of diabetes, and level of intervention. Abbreviations: BP, blood pressure; sBP, systolic blood pressure.

(TIF)
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Click here for additional data file.

###### Impact of self-monitoring of BP on clinic and ambulatory dBP at 6 months.

Change in dBP adjusted for age, sex, baseline clinic BP, history of diabetes, and level of intervention. Abbreviations: BP, blood pressure; dBP, diastolic blood pressure.

(TIF)

###### 

Click here for additional data file.

###### Change in sBP at 12 months including aggregate data from studies which did not contribute IPD for the primary analysis (19 studies).

\*Four studies containing aggregate data only: Varis et al. \[[@pmed.1002389.ref017]\], Rinfret et al. \[[@pmed.1002389.ref022]\], Artinian et al. \[[@pmed.1002389.ref018]\], and Kim et al. \[[@pmed.1002389.ref049]\]. Change in sBP from studies contributing IPD adjusted for age, sex, baseline clinic BP, and history of diabetes. Abbreviations: IPD, individual patient data; sBP, systolic blood pressure.

(TIF)

###### 

Click here for additional data file.

###### Primary analyses excluding all studies\* which did not use a home BP threshold which was lower than clinic BP.

Change in sBP at 12 months. \*Patients from TASMINH1 (Verberk et al. \[[@pmed.1002389.ref025]\] and McManus et al. \[[@pmed.1002389.ref024]\]) and diabetics from HINTS (Bosworth et al. \[[@pmed.1002389.ref026]\]) and TCYB (Bosworth et al. \[[@pmed.1002389.ref027]\]) all excluded. Change in sBP adjusted for age, sex, baseline clinic BP, and history of diabetes. Abbreviations: BP, blood pressure; sBP, systolic blood pressure.

(TIF)

###### 

Click here for additional data file.

###### Primary analyses (ABPM) excluding all studies which randomised patients on the basis of ABPM.

Change in sBP at 12 months. Change in sBP adjusted for age, sex, baseline clinic BP, history of diabetes, and level of intervention. Abbreviations: ABPM, ambulatory blood pressure monitoring; BP, blood pressure; sBP, systolic blood pressure.

(TIFF)

###### 

Click here for additional data file.

###### Primary analyses (ABPM) excluding all studies which randomised patients on the basis of clinic BP.

Change in sBP at 12 months. Change in sBP adjusted for age, sex, baseline clinic BP, history of diabetes, and level of intervention. Abbreviations: ABPM, ambulatory blood pressure monitoring; BP, blood pressure; sBP, systolic blood pressure.

(TIFF)

###### 

Click here for additional data file.

###### Impact of self-monitoring of BP on the RR of uncontrolled BP at 12 months, with patients lost to follow-up assumed to have controlled BP (15 studies).

RR of uncontrolled BP adjusted for age, sex, baseline clinic BP, and history of diabetes. Abbreviations: BP, blood pressure; RR, relative risk.

(TIF)

###### 

Click here for additional data file.

###### Impact of self-monitoring of BP on the RR of uncontrolled BP at 12 months, with patients lost to follow-up assumed to have uncontrolled BP (15 studies).

RR of uncontrolled BP adjusted for age, sex, baseline clinic BP, and history of diabetes. Abbreviations: BP, blood pressure; RR, relative risk.

(TIF)

###### 

Click here for additional data file.

###### Impact of self-monitoring of BP on clinic sBP at 12 months, with patients who had controlled BP at baseline excluded (15 studies).

Change in sBP adjusted for age, sex, baseline clinic BP, and history of diabetes. Abbreviations: BP, blood pressure; sBP, systolic blood pressure.

(TIF)

###### 

Click here for additional data file.

###### Studies which measured change in medication at follow-up.

sBP change at 12 months analysed without adjusting for medication changes at follow-up (11 studies). Change in sBP adjusted for age, sex, baseline clinic BP, and history of diabetes. Abbreviations: BP, blood pressure; sBP, systolic blood pressure.

(TIF)
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Click here for additional data file.

###### Studies which measured change in medication at follow-up.

sBP change at 12 months analysed adjusting for medication changes at follow-up (11 studies). Change in sBP adjusted for age, sex, baseline clinic BP, history of diabetes, and medication changes at 12 months follow-up. Abbreviations: BP, blood pressure; sBP, systolic blood pressure.

(TIF)
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Click here for additional data file.

###### Influence analysis presenting the pooled estimate of mean change in sBP at 12 months with each individual study omitted from the meta-analysis in turn.

Each line indicates pooled meta-analysis results with that study omitted from the results. Abbreviation: sBP, systolic blood pressure.

(TIFF)

###### 

Click here for additional data file.

###### Funnel plot showing mean change in sBP at 12 months.

The standard error is plotted against the mean change in sBP at 12 months. An Egger's test of zero (*P* = 1.00) would indicate little influence of publication bias. Abbreviation: sBP, systolic blood pressure.

(TIFF)

###### 

Click here for additional data file.

###### sBP change plotted against medication changes at 12 months follow-up, by level of intervention (11 studies).

\*Test for trend using a fixed-effects linear regression model adjusted for study. †The HOMERUS and TCYB trials, and studies by Godwin et al. \[[@pmed.1002389.ref043]\] and Leiva et al. \[[@pmed.1002389.ref046]\], were excluded due to missing data on medication changes at follow-up. Results where a negative change in BP is associated with a positive change in number of medications suggest medication intensification may be related to improved BP at 12 months. Abbreviation: BP, blood pressure; sBP, systolic blood pressure.

(TIFF)
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Click here for additional data file.

###### The STATA code used for the meta-analysis.

The STATA code used to perform the meta-analysis and figures.

(DOCX)

###### 

Click here for additional data file.
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